Abstract: The present disclosure relates to vaccine compositions comprising pneumococcal polysaccharide-carrier protein conjugates. The present disclosure particularly relates to improved, stable, immunogenic multivalent Streptococcus pneumoniae polysaccharide-protein conjugate vaccine compositions having at least three distinct carrier proteins, preparing the vaccine compositions and methods for prevention and/or treatment of subjects with Streptococcus pneumoniae. These multivalent pneumococcal compositions will overcome carrier induced epitopic suppression, provide enhanced immune response for new serotypes (as compared to existing approved vaccines) and also help address the emergence of non-vaccine serotypes.